Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...

Portal Hypertension

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Thalassaemia.

Nature reviews. Disease primers·2026

Same author

Targeting ineffective erythropoiesis in thalassemia: biologic therapies and emerging therapeutic strategies.

Expert opinion on biological therapy·2026

Same author

Addressing Obstetric and Gynecologic Needs in Thalassemia.

O&G open·2026

Same author

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026

Same author

When cure exists but access does not.

Nature medicine·2026

Same author

Patient-Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non-Transfusion-Dependent β-Thalassemia Treated in the BEYOND Trial.

European journal of haematology·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

The hypercoagulable state in thalassemia intermedia.

Ali T Taher¹, Khaled M Musallam, Adlette Inati

¹Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon. ataher@aub.edu.lb

|December 17, 2009

Summary

Beta-thalassemia patients, especially those with thalassemia intermedia, face a high risk of blood clots due to a hypercoagulable state. This review explores the causes and discusses strategies for preventing thrombosis in these individuals.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 17, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Area of Science:

Hematology
Vascular Biology
Genetics

Background:

Beta-thalassemia is a congenital blood disorder with improved life expectancy but persistent complications.
Thromboembolic events are a significant concern, particularly in beta-thalassemia intermedia.
A hypercoagulable state has been identified as a key factor contributing to thrombosis risk.

Purpose of the Study:

To review the molecular and cellular mechanisms underlying hypercoagulability in beta-thalassemia.
To focus on the heightened thrombotic risk in beta-thalassemia intermedia.
To discuss recommendations for thrombosis prophylaxis in affected patients.

Main Methods:

Literature review of studies on beta-thalassemia and hypercoagulability.
Analysis of molecular and cellular pathways involved in thrombosis.
Synthesis of current recommendations for thrombotic event prevention.

Main Results:

Hypercoagulability in beta-thalassemia is driven by complex molecular and cellular dysregulations.
Beta-thalassemia intermedia exhibits a significantly higher incidence of thrombotic events compared to other forms.
Specific risk factors and pathophysiological mechanisms contribute to this increased risk.

Conclusions:

Understanding the mechanisms of hypercoagulability is crucial for managing beta-thalassemia.
Thrombosis prophylaxis strategies are essential, especially for beta-thalassemia intermedia patients.
Further research is needed to optimize prevention and treatment of thromboembolic events in beta-thalassemia.